Regenerative Medicine
Explained: Peer-to-Peer Systems in Genesis RPA
Dr. Bankole Johnson’s video explores how GENESIS RPA (Robotic Process Automation) is revolutionizing Peer-to-Peer (P2P) systems. He explains that RPA boosts business efficiency by automating routine tasks and simplifying decentralized transactions. This reduces errors and improves workflows. Dr. Johnson also shares his insights on RPA’s future impact across industries and how businesses can use automation for a competitive edge in the digital age.
Forensics
Insights from a Leading Neuroscience Expert Witness
Bankole A. Johnson, DSc, MD, MBChB, MPhil, FRCPsych, DFAPA, Dip-ABAM, Dip-ABDA, FACFEI, is a leading Neuroscientist and respected global authority in both Psychiatry and Neuroscience. His considerable education and expertise date to the 1970s, when he received his first general studies diploma.
Addiction
Research & Insights
Dr. Johnson’s early research (1990-1993) covered lofepramine toxicity, cannabis effects, mood disorders, psychosis, temporal lobe damage, substance misuse, amphetamine behavior, ondansetron, and computer applications in psychiatry.
Further studies (1993-1998) explored 5-HT3 blockade on alcohol mood, GR 68755 on amphetamine effects, ritanserin for alcohol and cocaine dependence, brain blood flow in cocaine users, cue reactivity, isradipine’s role in cocaine-induced blood flow reduction, intravenous cocaine’s impact, and bipolar diagnosis stability.
In 2004, Johnson reviewed topiramate for alcohol dependence and its applications, its role in dopamine function, its positive impact on life quality for alcohol-dependent individuals (with colleagues), novel anticonvulsants for alcohol dependence, long-acting naltrexone, and the serotonergic system in alcoholism treatment.
2005 studies investigated serotonin transporter genotypes in alcoholics (Javors et al.), isradipine formulations in cocaine dependence (Johnson et al.), pharmacist attitudes toward buprenorphine/naloxone (Raisch et al.), GABAergic medications for alcoholism (Johnson et al.), isradipine on methamphetamine cognition (Roache et al.), alcoholism biomarkers (Wurst et al.), and long-acting naltrexone efficacy (Garbutt et al.).
More 2005 research by Johnson et al. examined isradipine on stimulant responses and cocaine-induced blood flow, ondansetron in adolescents (Dawes et al.), and topiramate for smoking cessation in alcohol-dependent individuals (Johnson et al.).
In 2006, Johnson and colleagues studied alcohol dependence treatments: the COMBINE SAFTEE instrument, international collaborations, alcohol/nicotine co-morbidity.
Johnson summarized treatments for alcohol/cocaine dependence, Dawes et al. linked craving reduction to drinking reduction, Johnson et al. assessed isradipine on cocaine abuse liability, Anton et al. reported on combined alcohol dependence pharmacotherapies, and Johnson reviewed naltrexone depot, commented on cocaine dependence, and wrote on smoking cessation.
Ait-Daoud et al. (2006) explored smoking dependence in depressed alcoholics. Johnson et al. (2007) investigated topiramate’s effects on methamphetamine cognition and mood, as well as its kinetic and cardiovascular effects. Penberthy et al. (2007) analyzed alcohol dependence treatment readiness. A major study by Johnson et al. (2007) evaluated topiramate for alcohol dependence, and Johnson (2007) reviewed long-acting naltrexone.
Johnson (2008) updated neuropharmacological alcoholism treatments. Donovan et al. (2008) assessed post-treatment drinking outcomes. Johnson et al. (2008) examined the serotonin transporter genotype in alcoholism and ondansetron for methamphetamine dependence. Soyka et al. (2008) outlined alcoholism treatment guidelines. Johnson et al. (2008) showed topiramate’s health benefits for alcohol-dependent individuals. Liu et al. (2008) introduced a statistical model for alcohol dependence research.
Roache et al. (2008) predicted serotonergic treatment efficacy. Zarkin et al. (2008) analyzed the COMBINE study’s cost-effectiveness. Weiss et al. (2008) questioned placebo response in alcohol dependence treatment.
Seneviratne et al. (2009) studied genetic polymorphisms and drinking intensity, while Ait-Daoud et al. (2009) assessed the serotonin transporter genotype in alcohol craving. Seneviratne et al. (2009) identified a genetic susceptibility locus for alcohol dependence. Dawes et al. (2009) explored drinking histories of alcohol-use-disordered youth. Breslin et al. (2010) tested topiramate on ethanol consumption in rats. Johnson (2010) discussed pharmacological treatments for different alcoholism types. Johnson and Ait-Daoud (2010) examined topiramate in modern alcoholism treatment. Johnson et al. (2010) linked serotonin transporter genotype to methamphetamine use onset.
Falk et al. (2010) proposed a new endpoint for alcohol trials. Johnson et al. (2011) explored pharmacogenetics in reducing alcohol consumption severity and discussed NIH’s addiction research reorganization. Penberthy et al. (2011) analyzed motivational changes’ impact on drinking. Lynch et al. (2011) examined combined ondansetron and topiramate effects on ethanol consumption. Kovatchev et al. (2012) introduced in silico models of alcohol dependence. Ait-Daoud et al. (2012) linked serotonin transporter gene polymorphism to alcohol craving.
Litten et al. (2012) evaluated quetiapine fumarate for alcohol dependence. Vaughan et al. (2012) studied affect changes and drinking outcomes. Seneviratne and Johnson (2012) identified a serotonin transporter biomarker for ondansetron response. Elkashef et al. (2012) conducted a topiramate trial for methamphetamine addiction. Fertig et al. (2012) assessed levetiracetam extended-release efficacy. Chen et al. (2012) applied trajectory analyses in alcohol treatment research. Wages et al. (2012) developed optimal dosing strategies for alcohol dependence.
Books
Six Rings
The Six Rings book series is interested in analyzing the complexities of the brain and how to maintain it in optimum health. This is not a new-age book about brain enhancements to expand one’s consciousness and awareness of things around you. Rather, the book discusses the issues surrounding how we can keep our minds in an ideal state and improve its functioning, with a focus on addiction medicine and psychiatry. He is not your regular run-of-the-mill doctor. He`s smart as a whip, adept at multiple disciplines and focused on improving the science of addiction medicine and psychiatry.
Addiction Medicine: Science and Practice, Second Edition
Integrating scientific knowledge with today`s most effective treatment options, Addiction Medicine: Science and Practice provides a comprehensive and practical guide to the diagnosis, treatment, and prevention of addiction. The book covers the neuroscience of addiction, pharmacological treatments, behavioral therapies, and social implications of addiction medicine. This essential text is ideal for anyone who deals with patients with addictions, including physicians, psychologists, social workers, and other healthcare professionals. It provides state-of-the-art information on the latest advancements in addiction science and treatment methods equipping practitioners with the tools needed to address addiction comprehensively.
Addiction Medicine: Science and Practice
The spectrum of addiction disorders presents practitioners with numerous challenges—among them the widening gap between a growing evidence base and the translation of this knowledge into treatment outcomes. Addiction Medicine: Science and Practice provides a comprehensive exploration of substance use disorders, their diagnosis, and management strategies. This book aims to bridge this gap by presenting state-of-the-art information on the medical aspects of addiction, incorporating the latest research on neurobiology, pharmacology, behavioral interventions in addiction treatment.
Drug Addiction and Its Treatment
Increasing interest in neuroscience research has uncovered a need to understand how behavioral and neurological factors contribute to drug addiction. Drug Addiction and Its Treatment offers an in-depth analysis of addiction neuroscience and treatment modalities. This text is a reference for neuroscientists, behavioral psychologists, addiction specialists and healthcare providers. It explores the underlying mechanisms of addiction, from neurochemical pathways to behavioral conditioning, and presents a variety of treatment approaches aimed at managing and overcoming drug dependence.
Publish Abstract
| Johnson et al. found that blocking 5-HT3 receptors reduced the rewarding effects of alcohol (1992). |
| Johnson et al. studied ritanserin and its effect on alcohol craving and consumption in patients (1995). |
| Johnson et al. investigated naltrexone for individuals with both alcohol and nicotine dependence (1996). |
| Rafieha et al. examined how work requirements and naltrexone affected alcohol self-administration in humans (1996). |
| Johnson et al. and Barron et al. (in separate studies) looked at brain perfusion abnormalities in cocaine abusers after cocaine use (1997). |
| Barron et al. investigated isradipine’s effect on cocaine-induced brain perfusion changes (1997). |
| Johnson et al. and Lamki et al. (in separate publications) studied how isradipine could reverse cocaine-induced changes in brain blood flow (1997/1998). |
| Shafer et al. examined the sensitivity of a lab method for studying cue reactivity (1997/1998). |
| Overton et al. studied the cardiovascular effects of cocaine (1997/1998). |
| Chen et al. researched cue reactivity and its specificity (1997/1998). |
| Johnson et al. explored the link between childhood problems and early-onset alcoholism (1998). |
| Johnson et al. conducted a preliminary analysis on ondansetron’s effects on alcohol consumption (1999). |
| Ait-Daoud et al. looked at the safety and effectiveness of combining ondansetron and naltrexone for alcoholism (2000). |
| Johnson et al. and Ait-Daoud et al. (in separate studies) investigated how craving and the age of onset of alcoholism relate to ondansetron treatment (2001). |
| Ait-Daoud et al. studied the correlation between craving and drinking in alcoholics treated with ondansetron (2001). |
| Ait-Daoud et al. explored the combined effect of ondansetron and naltrexone in reducing alcohol consumption in early-onset alcoholics, using CDT levels as confirmation (2001). |
| Johnson et al. compared slow-release and standard isradipine for potential methamphetamine dependence treatment (2001). |
| Murff et al. studied behavioral management for cocaine-dependent patients who used sedatives (2001). |
| Ait-Daoud and Johnson investigated the combined effects of ondansetron and naltrexone on craving and drinking in early-onset alcoholism (2001). |
| Johnson and Ait-Daoud explored a genetic approach to treating early-onset alcoholism with ondansetron (2001). |
| Johnson studied ondansetron’s effectiveness in biologically predisposed alcoholic patients (2001). |
| Ait-Daoud et al. examined the short-term effects of isradipine on blood pressure responses in cocaine dependence trials (2002). |
| Johnson et al. studied isradipine’s impact on cocaine-induced euphoria and craving (2002). |
| Murff et al. looked at the side effects of isradipine in cocaine dependence trials (2002). |
| Roache et al. developed a lab model to study cues related to cocaine use and relapse prevention (2002). |
| Johnson presented on the development of topiramate for alcoholism treatment (2003). |
| Roache and Johnson discussed ondansetron as a treatment for “biological” alcoholism (2003). |
| Johnson explored the use of mood stabilizers for alcoholism (2003). |
| Johnson studied topiramate’s effect on smoking in individuals dependent on both alcohol and nicotine (2004). |
| Johnson examined combining topiramate and ondansetron for alcoholism treatment (2004). |
| Johnson and Ait-Daoud presented safety and effectiveness data on topiramate for alcohol dependence (2004). |
| Javors et al. discussed the use of biomarkers to assess the effectiveness of alcoholism medications (2004). |
| Javors et al. explored serotonin uptake in platelets of alcoholic subtypes with different serotonin transporter genes (2004). |
| Seneviratne et al. analyzed differences in platelet serotonin uptake in alcoholic subtypes with genetic variations in the serotonin transporter (2004). |
| Roache et al. examined how different types and onset times of alcoholism predict baseline severity and response to ondansetron (2004). |
| Johnson presented on using medication to help alcohol-dependent individuals quit nicotine (2004). |
| Wurst et al. examined direct ethanol byproducts as potential biomarkers for alcohol use (2004). |
| Wurst et al. further investigated direct ethanol byproducts as biomarkers (2005). |
| Johnson and Ait-Daoud shared new data on topiramate for alcohol dependence (2004). |
| Javors et al. discussed the role of biomarkers in assessing alcoholism medication effectiveness (2004). |
| Javors et al. studied serotonin uptake in platelets among alcoholic subtypes with different serotonin transporter genotypes (2004). |
| Seneviratne et al. analyzed platelet serotonin uptake differences in alcoholic subtypes with variations in the serotonin transporter gene (2004). |
| Roache et al. found that Type A/B alcoholism predicts baseline severity, while early/late onset predicts ondansetron response (2004). |
| Johnson presented on using medication to promote nicotine abstinence in alcohol-dependent individuals (2004). |
Explore News Article, HBO Addiction: Award-Winning Interview and Debuts “Six Rings” Trilogy
The Addict’s Brain (Newsweek)
In the HBO Addiction series, my work with interviews of patients and my discovery is in section 9. This work won 2 Emmy Awards including the Governor’s Emmy Award
Dr. Bankole Johnson Debuts “Six Rings” Trilogy
In the first installment of a two part interview, Hackie Reitman, M.D. speaks with Bankole A. Johnson, DSc, MD, MBChB, MPhil, FRCPsych, DFAPA, Dip-ABAM, Dip-ABDA, FACFEI, who heads the Brain Science Research Consortium Unit (BSRCU) at the University of Maryland School of Medicine, and is one of the world’s leading authorities on the subject of addiction. He is a leading neuroscientist and a pioneer in the development of medications for the treatment of alcohol abuse, and was featured on the HBO documentary series, “Addiction.” Professor Johnson discusses the ties between addiction and neurodiversity, how discoveries in neuroscience may change the way substance abuse is treated, and the importance of understanding the relationship between the body and the brain.
Neuropsychiatry
Research & Insights
In 1992, Johnson and colleagues discovered that blocking certain receptors in the brain (called 5-HT3 receptors) reduced the pleasurable effects of alcohol.
In 1995, Johnson and his team studied the drug ritanserin to see if it could lessen the desire for alcohol and reduce drinking in patients who were abusing alcohol.
Johnson and others in 1996 researched the use of the medication naltrexone for people who were dependent on both alcohol and nicotine.
Rafieha, Spiga, Macenski, Meisch, Grabowski, and Johnson in 1996 investigated how requiring work and giving naltrexone affected how much alcohol people would voluntarily drink.
In 1997, Johnson and colleagues, as well as Barron and colleagues in a separate study, used brain imaging techniques to look for unusual blood flow patterns in the brains of cocaine abusers after they used cocaine.
Barron and others in 1997 studied the drug isradipine to see if it had any effect on the changes in brain blood flow caused by cocaine.
Research published around 1997 and 1998 by Johnson’s team and Lamki’s team (in different publications) explored whether isradipine could reverse the changes in brain blood flow that cocaine causes.
Shafer and colleagues in research around 1997 and 1998 examined how sensitive a laboratory method was for studying how people react to cues related to drug use.
Overton and others in research around 1997 and 1998 studied the effects of cocaine on the heart and blood vessels.
Chen and colleagues in research around 1997 and 1998 investigated how specific the reactions to drug-related cues were.
In 1998, Johnson and his team explored whether problems experienced in childhood were linked to developing alcoholism at an early age.
Johnson and colleagues in 1999 conducted an initial analysis of a study where some participants received the drug ondansetron and others a placebo, to see how it affected their alcohol consumption.
In 2000, Ait-Daoud, Prihoda, and Johnson looked at how safe and effective it was to use both ondansetron and naltrexone together to treat alcoholism.
In 2001, Johnson and colleagues, and Ait-Daoud and colleagues in a separate study, investigated how the intensity of alcohol craving and the age when someone started drinking affected how well ondansetron treatment worked.
Ait-Daoud and others in 2001 studied the relationship between different ways of measuring alcohol craving and how much alcohol alcoholics drank while they were being treated with ondansetron.
Ait-Daoud, Johnson, Roache, Javors, and Zanca in 2001 explored if using both ondansetron and naltrexone could reduce alcohol consumption in people who started drinking heavily at a young age. They also used a blood marker (serum CDT levels) to confirm their findings.
In 2001, Johnson, Roache, and Ait-Daoud compared how the body processed and how long the effects lasted for two different forms of isradipine (slow-release and standard) to see if it could be a treatment for methamphetamine dependence.
Murff, Roache, Thornton, Robinson, and Johnson in 2001 studied how to manage the behavior of cocaine-dependent patients in a residential treatment setting who were also using sedatives to self-medicate.
Ait-Daoud and Johnson in 2001 investigated how combining ondansetron and naltrexone affected craving, drinking behavior, and the interaction between the two in people with early-onset alcoholism.
In 2001, Johnson and Ait-Daoud explored a way to tailor alcoholism treatment based on a person’s genes, using ondansetron, and linked their findings to different types of alcoholism.
Johnson in 2001 studied how well ondansetron worked to reduce alcohol consumption in alcoholic patients who had a biological predisposition to alcoholism.
Ait-Daoud and colleagues in 2002 examined the short-term effects of isradipine on blood pressure responses in studies looking at its potential as a treatment for cocaine dependence.
In 2002, Johnson and his team studied how sub-acute (not immediate, but short-term) doses of isradipine affected the feelings of euphoria and the craving for cocaine in clinical trials.
Murff and others in 2002 looked at the side effects that occurred when isradipine was used in clinical trials for cocaine dependence treatment.
Roache and colleagues in 2002 developed a laboratory method to study the internal thoughts and external triggers that are related to the reinforcing effects of cocaine and relapse prevention.
In 2003, Johnson presented research on the development of the drug topiramate as a treatment for alcoholism.
Roache and Johnson in 2003 discussed the use of ondansetron as a treatment for a type of alcoholism that might have a biological basis.
Johnson in 2003 explored the use of mood-stabilizing medications to treat alcoholism, focusing on how they work and new research findings.
In 2004, Johnson studied the effect of topiramate on tobacco smoking in people who were dependent on both alcohol and nicotine.
Johnson in 2004 examined the possibility of combining new medications, specifically topiramate and ondansetron, to treat alcoholism.
In 2004, Johnson and Ait-Daoud presented new information about how safe and effective topiramate was for treating alcohol dependence.
Javors, Johnson, Ait-Daoud, Weinmann, and Wurst in 2004 discussed how useful biological markers could be in determining if medications for alcoholism were working.
Javors and colleagues in 2004 explored how the uptake of serotonin (a brain chemical) in blood platelets differed among different types of alcoholics who had different versions of a gene related to serotonin transport.
Seneviratne and others in 2004 analyzed the differences in how serotonin was taken up by platelets in different types of alcoholics who had genetic variations in the serotonin transporter gene.
Roache, Wang, Ait-Daoud, and Johnson in 2004 examined how different categories of alcoholism (Type A/B) predicted the initial severity of the problem, while the age of onset (early vs. late) predicted how well someone would respond to ondansetron treatment.
Johnson in 2004 presented research on using medications to help people who were dependent on alcohol to also stop using nicotine.
Wurst and colleagues in 2004 examined direct byproducts of alcohol in the body, such as ethyl glucuronide (EtG), as potential markers to detect alcohol use.
Wurst and others in 2005 further investigated various direct byproducts of alcohol as sensitive and specific indicators of alcohol consumption.
In 2004, Johnson further investigated pharmacological treatments for substance abuse, including the effects of naltrexone on how much alcohol monkeys would drink and isradipine’s role in heart and blood vessel responses to cocaine.
His work in 1999 also looked at whether different ethnic groups responded differently to neuroleptic medications for schizophrenia and if there was a link between the availability of the amino acid tryptophan in the blood and alcoholism.
Additionally, he explored the use of ondansetron and naltrexone in treating alcohol dependence (published in 2000), the brain chemistry behind alcoholism treatment (also 2000), and how ondansetron affected the craving for alcohol (published in JAMA in 2000).
His later research in 2003 looked into genetic factors involved in alcoholism, the combination of drug therapy and behavioral treatments for alcohol dependence (The COMBINE Study), and how well oral topiramate worked for treating alcoholism (published in The Lancet in 2003). Throughout his career, Dr. Johnson has made significant contributions to understanding and treating addiction, mood disorders, and other psychiatric conditions through clinical trials and studies of medications.
In 2003, Sloan, Roache, and Johnson explored how anxiety might predict drinking behavior. Also in 2003, Johnson examined the role of medications that affect serotonin in treating alcoholism. Javors and Johnson in 2003 discussed biological markers in the body that could indicate alcohol consumption. Additionally, Johnson and colleagues in 2003 showed how ondansetron could reduce mood disturbances in alcohol-dependent individuals who were biologically predisposed. In 2004, McBride and others investigated serotonin-3 receptors in how alcohol reinforces drinking and in alcoholism itself, while Johnson and colleagues in 2004 focused on developing new drug treatments for alcohol dependence, particularly antiepileptic medications.
In 2004, Johnson and colleagues examined the effects of isradipine on changes in mood caused by cocaine. Also in 2004, Dawes and Johnson highlighted the opportunities and challenges in conducting drug treatment trials for alcohol use disorders in adolescents. Johnson in 2004 explored the biological basis of alcohol dependence, and
Lam and colleagues in 2004 studied how well different formulations of ondansetron were absorbed by the body. Kranzler and colleagues in 2004 conducted a study on a long-acting injectable form of naltrexone for alcohol dependence. Anton and others in 2004 conducted a study to find the best dose of the drug nalmefene for alcohol dependence, and Littleton and colleagues in 2004 discussed the difficulties in developing new medications in an international meeting.
Publish Abstract
Swann, A.C., Chen, Y.R., Johnson, B.A. (1998). Serotonin and alcoholism: relationships between tryptophan availability and clinical features. Research Society on Alcoholism Annual Meeting, Hilton Head, South Carolina, 1998. Alcoholism: Clinical and Experimental Research, 22 (suppl 3): 85A, 1998.
Ait-Daoud, N., Prihoda, T., and Johnson, B.A. (2000). Investigated the safety and effectiveness of combining ondansetron and naltrexone for alcoholism treatment. Presented at the Collegium Internationale Neuro-psychopharmacologicum Congress, Brussels, Belgium, 2000. Published in The International Journal of Neuropsychopharmacology, 3 (suppl 1): S311, 2000.
Johnson, B., and Ait-Daoud, N. (2001). Examined the use of ondansetron for treating early-onset alcoholism through a pharmacogenetic approach to the subtype concept. Presented at the 7th World Congress of Biological Psychiatry, Berlin, Germany, 2001. Published in World Journal of Biological Psychiatry, 2 (suppl 1): 40S, 2001.
Roache, J.D., and Johnson, B.A. (2003). Explored the potential of ondansetron as a treatment for “biological” alcoholism. Presented in the symposium titled “Serotonin-3 receptors in the actions of alcohol, alcohol reinforcement, and alcoholism”, chaired by W.J. McBride and D.M. Lovinger, at the Research Society on Alcoholism Annual Meeting, Fort Lauderdale, Florida, 2003. Published in Alcoholism: Clinical and Experimental Research, 27 (suppl 5): 167A, 2003.
Ait-Daoud, N., and Johnson, B. (2002). Studied the use of ondansetron with and without naltrexone as a treatment for biological alcoholism, presenting concepts and updated findings. Presented at the 15th European College of Neuropsychopharmacology Congress, Barcelona, Spain, 2002. Published in European Neuropsychopharmacology, 12 (suppl 3): S396, 2002.
Johnson, B.A. (2004). Discussed the development of topiramate for the treatment of alcoholism. Presented in the symposium titled “New pharmacologic treatments of alcoholism”, chaired by B. Johnson and O. Lesch, at the Collegium Internationale Neuro-psychopharmacologicum Congress, Paris, France, 2004. Published in The International Journal of Neuropsychopharmacology, 7 (suppl 1): S12, 2004.
Johnson, B.A. (2006). Conducted association studies on the 5′-HTTLPR gene polymorphism, alcohol craving, and treatment response to ondansetron. Presented in the symposium titled “Serotonergic modulation of behavioural and neurochemical actions of alcohol: evidence from the bench to the clinic”, chaired by L.C. Daws and A. Holmes, at the International Society for Biomedical Research on Alcoholism, World Congress on Alcohol Research, Sydney, Australia, 2006. Published in Alcoholism: Clinical and Experimental Research, 30 (s2): 99A, 2006.
Johnson, B.A., Rosenthal, N., Capece, J., Wiegand, F., Mao, L., Beyers, K., McKay, A., Ait-Daoud, N., for the Topiramate for Alcoholism Study Group (2007). Presented results of a multi-site trial on topiramate for the treatment of alcohol dependence in the symposium titled “On the development of topiramate as a treatment for alcohol dependence: the next generation of progress in pharmacotherapy”, chaired by B. Johnson and R. Litten, at the Research Society on Alcoholism Annual Meeting, Chicago, Illinois, 2007. Published in Alcoholism: Clinical and Experimental Research, 31 (s2): 261A, 2007.
Innovative Research and Treatment for Alcohol Dependence
Books
The Rehab Myth: New Medications that Conquer Alcoholism
Unbeknownst to most Americans, there are a range of safe medications that are very effective in treating alcoholism—medications that can save lives and make the difference between hope and despair, and yet are often overlooked in traditional rehabilitation programs. These medications, when combined with the right behavioral strategies, can significantly improve recovery rates and help individuals regain control over their lives. This new alcoholism recovery plan offers unprecedented options that go beyond traditional 12-step programs. It provides evidence-based medical treatments that can help patients achieve lasting sobriety with fewer relapses.
Handbook of Clinical Alcoholism Treatment
Written by leading experts, this handbook is a practical, accessible guide to the diagnosis and treatment of alcoholism. Covering both the theoretical and practical aspects of alcoholism treatment, it provides clinicians with the essential knowledge and strategies needed to manage alcohol dependence effectively. The chapters focus on specific treatment settings, including inpatient, outpatient, and community-based programs, as well as strategies for addressing co-occurring disorders and relapse prevention.
Publish Abstract
Fang, Lamki, Barron, Williams, Johnson, and Wagner (1996) investigated accurate methods for measuring cerebral blood flow using nuclear medicine imaging techniques (TC-HMPAO and TC-ECD), presenting their findings at a conference and later publishing them in Clinical Nuclear Medicine. Johnson, Chen, Roache, Swann, and Bordnick (1998) examined whether the age of onset of heavy drinking could help identify different subtypes of alcoholism, presenting their work at the Research Society on Alcoholism (RSA) Annual Meeting and publishing it in Alcoholism: Clinical and Experimental Research. In the same year, Bordnick, Shenberger, Hassan, Doherty, and Johnson (1998) explored how the age at which drinking began related to treatment retention in alcohol programs, also presented at the RSA Annual Meeting and published in the same journal. Javors, Garza, Chen, and Johnson (1998) analyzed the relationship between biological alcohol-use markers (CDT and GGT) and self-reported drinking over time using hierarchical linear modeling, presented at the RSA Meeting and published in Alcoholism: Clinical and Experimental Research. Durgam, Tiouririne, Shenberger, Jones, and Johnson (1999) evaluated the effectiveness of telephone screening for selecting appropriate participants for outpatient alcoholism clinical trials, presenting their findings at the RSA Annual Meeting and publishing them in the same journal. Tiouririne, Prihoda, and Johnson (1999) conducted two studies: one comparing men and women with early- vs. late-onset alcoholism, presented at the RSA Annual Meeting and published in Alcoholism: Clinical and Experimental Research; and another examining maternal familial links among alcoholic women, presented at the College on Problems of Drug Dependence Annual Meeting and published in its proceedings.
Johnson (2002) discussed the development and potential of ondansetron as a treatment for individuals with a biological predisposition to alcoholism, presenting this at the Collegium Internationale Neuro-psychopharmacologicum Congress and publishing it in The International Journal of Neuropsychopharmacology. Ait-Daoud, Johnson, Velazquez, Lawson, Roache, and Javors (2002) investigated the relationship between self-reported and objective measures of alcohol consumption among genetically predisposed individuals, presenting their findings at the RSA Meeting and publishing them in Alcoholism: Clinical and Experimental Research. Stoks, Johnson, Roache, Sloan, Hoerster, and DiClemente (2002) explored whether alcohol craving intensity and temptation predicted drinking behavior in clinical trials, while Sloan, Roache, Johnson, Stoks, and Hoerster (2002) examined whether baseline anxiety predicted treatment response to ondansetron in early-onset alcoholics; both studies were presented at the RSA Meeting and published in Alcoholism: Clinical and Experimental Research. Johnson (2003) presented emerging research on mood stabilizers for alcoholism treatment at the European Society for Biomedical Research on Alcoholism Meeting, later published in Alcohol and Alcoholism. Javors, Johnson, Ait-Daoud, Weinmann, and Wurst (2004) evaluated the usefulness of biological markers in assessing medication efficacy for alcoholism, presented at the RSA Meeting and published in Alcoholism: Clinical and Experimental Research. In the same year, Johnson (2004) provided an expert academic perspective on medication development for alcoholism, emphasizing academia-industry collaboration, presented at the ISBRA World Congress and published in the same journal.
Seneviratne, Javors, Roache, Dawes, Ait-Daoud, and Johnson (2005) studied the influence of current drinking habits on serotonin transporter activity in treatment-seeking alcoholics with different genetic variants, presenting a poster at the RSA Meeting and publishing in Alcoholism: Clinical and Experimental Research. Johnson and Ait-Daoud (2006) explored genetic and biological predictors of medication response for alcohol dependence, presented at the RSA Meeting and published in the same journal. Wurst et al. (2006) evaluated direct alcohol metabolites such as ethyl glucuronide and ethyl sulfate for diagnosis and treatment monitoring, presented at the ISBRA World Congress and published in Alcoholism: Clinical and Experimental Research. Lynch and Johnson (2007) investigated topiramate’s effects on alcohol consumption in rats, presented in a symposium on topiramate development at the RSA Meeting and published in the same journal. O’Malley, Couper, Anton, Hosking, Johnson, and Mason (2007) conducted in-depth analyses of drinking patterns in the COMBINE Study, presented as a poster at the RSA Meeting and published in Alcoholism: Clinical and Experimental Research.
Johnson and Ait-Daoud (2008) conducted a preliminary clinical trial examining the combined use of ondansetron and olanzapine for alcohol dependence, presenting the results at a joint RSA–ISBRA Meeting and publishing them in Alcoholism: Clinical and Experimental Research. Donovan et al. (2008) identified predictors of treatment outcomes with naltrexone and acamprosate, presenting the findings at a joint RSA–ISBRA symposium and publishing them in the same journal. Wurst et al. (2008), on behalf of the WHO/ISBRA Collaborative Study, explored new biomarkers for alcohol use, presenting their work at the joint RSA–ISBRA symposium and publishing it in Alcoholism: Clinical and Experimental Research. Ait-Daoud, Haughey, and Johnson (2009) tested whether topiramate could help women with both alcohol dependence and binge-eating disorder, presenting a poster at the RSA Meeting and publishing in the same journal. Falk, Wang, Liu, Fertig, Mattson, Ryan, Johnson, Stout, and Litten (2010) evaluated percentage of non-heavy drinking days as a clinical trial outcome measure, presenting at the ISBRA World Congress and publishing in Alcoholism: Clinical and Experimental Research. Johnson and Liu (2010) discussed innovative analytical approaches focusing on individual variability in alcohol-treatment research, presenting at the ISBRA World Congress and publishing in the same journal.
Lynch, Bond, Breslin, and Johnson (2011) explored combined ondansetron and topiramate effects on alcohol consumption in rats based on drinking severity, presenting a poster at the RSA Meeting and publishing their results in Alcoholism: Clinical and Experimental Research. Finally, Johnson (2011) delivered a plenary lecture on medical treatments for alcoholism at the European Society for Biomedical Research on Alcoholism Meeting, later published in Alcohol and Alcoholism.
Innovative Research and Treatment for Alcohol Dependence
Vision, Achievements, Insights and Legacy
Resume – Resume Link
Professional Overview View Profile
The founder of Adial Pharmaceuticals, who served as Chairman and led the company to the NASDAQ, now also serves as its Chief Medical Officer (CMO). My Journey with Adial Pharmaceuticals
A renowned neuroscientist posits that true beauty originates in the brain. By understanding and enhancing brain function, individuals can achieve greater happiness and well-being, which in turn reflects in their outward appearance. This approach suggests that mental health and cognitive optimization are integral to one’s perception of beauty. Beauty & the Brain
Five key strategies to optimize mental wellness include prioritizing self-care, maintaining healthy relationships, ensuring good sleep hygiene, engaging in regular physical activity and practicing relaxation techniques such as meditation and deep breathing. These simple habits help reduce stress, boost mood, and enhance overall well-being. 5 Wellness Strategies
Starting the day with a healthy routine is key to boosting brain function and overall well-being. A recommended approach includes drinking high pH water and a brain juice rich in antioxidants, essential nutrients, and gut-friendly ingredients. This morning ritual helps reduce oxidative stress, support metabolism, and enhance heart and immune health—creating a simple yet powerful start to the day. Healthy Morning with Brain Juice
A doctor explains who should receive a COVID-19 booster shot: The chief medical officer of Adial Pharmaceuticals emphasizes that booster shots are especially important for individuals who are immunocompromised and notes that healthy individuals will also likely need a third vaccine dose. Expert Advice on Booster Shots
Medical Perspective on COVID-19 and Back-to-School Planning. COVID & the New School Year video
A leading medical expert says Merck’s new COVID-19 pill is an exciting development. Merck’s COVID Pill: Expert Opinion
The founder and Chief Medical Officer of Adial was honored to be a guest on The Black News Channel (BNC). During the interview, concerns were raised about a second, hidden pandemic. Watch Dr. Johnson on BNC
Some construction photos from our $1M renovation. View Construction Photos
Casa Privée Digital Brochure Open Casa Privée Brochure